by Sean Keyes | Financial Correspondant
Serial dealmaker Cathal Friel has an audacious plan: build and sell a pharma services company in two years. It could fetch as much as £100 million. What exactly is his plan? And will it work?
On the cover of the fifth edition of Dr John Oxford’s book Human Virology is a picture of the Wuhan strain of the coronavirus. It was published in 2016.
The virus spherical, with hundreds of nasty looking bulbous projections on its surface. Viewed through a microscope, the projections resemble the sun’s corona. Hence the name.
Showing me Dr Oxford’s book is Cathal Friel, the Chairman of the small cap pharma services company Open Orphan (LN:ORPH). Friel is showing me the book because five weeks ago his company, Open Orphan, acquired the virus-fighting company founded by Dr Oxford.
The company is called hViVo….
Link here to login and read full article